The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study.
 
Macarena Ines De La Fuente
Consulting or Advisory Role - ADC Therapeutics (I); Agios; Pyramid Biosciences
Research Funding - ADC Therapeutics (I)
 
Jordi Rodon Ahnert
Consulting or Advisory Role - AADi; Avoro Capital Advisors; Boxer Capital; Chinese University of Hong Kong; Clarion Healthcare; Columbus Venture Partners; Cullgen; Debiopharm Group; Ellipses Pharma; Envision Pharma Group; iOnctura; Macrogenics; Merus; Monte Rosa Therapeutics; Monte Rosa Therapeutics; Oncology One; Pfizer; Sardona Therapeutics; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
Research Funding - AADi (Inst); Amgen (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cellestia Biotech (Inst); Curis (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Kelun (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Takeda/Millennium (Inst); Tango Therapeutics (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - ESMO
Other Relationship - Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Rona Yaeger
Honoraria - Zai Lab
Consulting or Advisory Role - Mirati Therapeutics
Research Funding - Array BioPharma (Inst); Boehringer Ingelheim (Inst); Mirati Therapeutics (Inst); Pfizer (Inst)
 
Frank Yung-Chin Tsai
Stock and Other Ownership Interests - Salarius Pharmaceuticals
Consulting or Advisory Role - Aptitude Health; Aptitude Health; Aptitude Health; Tempus
Patents, Royalties, Other Intellectual Property - Clinical trial software.
 
Filip Janku
Employment - Monte Rosa Therapeutics
Leadership - Monte Rosa Therapeutics
Stock and Other Ownership Interests - Cardiff Oncology; Monte Rosa Therapeutics
Consulting or Advisory Role - Cardiff Oncology; Deciphera; Fore Biotherapeutics; Foundation Medicine; Guardant Health; IDEAYA Biosciences; IFM Therapeutics; Immunomet; Jazz Pharmaceuticals; Novartis; Novartis; PureTech; Sequenom; Sotio; Synlogic; Valeant/Dendreon
Research Funding - Agios (Inst); Asana Biosciences (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Fujifilm (Inst); Genentech (Inst); Novartis (Inst); Piqur (Inst); Plexxikon (Inst); Proximagen (Inst); Roche (Inst); Symphogen (Inst)
Other Relationship - Bio-Rad
 
Nicholas A. Butowski
Stock and Other Ownership Interests - Cordance; Cordance
Consulting or Advisory Role - DelMar Pharmaceuticals; Gan & Lee; IN8Bio; Ipsen; KIYATEC; Novartis; Plus Therapeutics; Sagimet Biosciences; VBI Vaccines; VBL Therapeutics
Research Funding - Abbvie (Inst); Amgen; Amgen (Inst); Arbor Pharmaceuticals (Inst); BeiGene (Inst); BeiGene (Inst); BioMimetix (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); EpicentRx; Five Prime Therapeutics; Ipsen; Istari (Inst); KIYATEC (Inst); Medicenna; Merck; Oncoceutics (Inst); Orbus Therapeutics; Tocagen (Inst)
 
Carl E. Allen
Consulting or Advisory Role - Genentech/Roche; Sobi
Research Funding - Genentech/Roche; NovImmune
 
Natraj Reddy Ammakkanavar
Stock and Other Ownership Interests - Cardiff Oncology; Iovance Biotherapeutics
Consulting or Advisory Role - AstraZeneca/MedImmune
Speakers' Bureau - Bristol-Myers Squibb/Celgene; Sanofi/Regeneron
 
Jennie Webster Taylor
Research Funding - Abbvie; Agios; Bristol-Myers Squibb; Navio Theragnostics (Inst)
Other Relationship - Mount Sinai Health System; University of Colorado
 
Glenn Michelson
Other Relationship - Fore Biotherapeutics
 
Irina Kline
Employment - Bristol Myers Squibb Foundation; Fore Biotherapeutics; Johnson & Johnson
Stock and Other Ownership Interests - Fore Biotherapeutics
 
Michael Paz
Employment - Fore Biotherapeutics; Syneos Health
Stock and Other Ownership Interests - Abbvie; Bristol-Myers Squibb/Celgene; Fore Biotherapeutics; Syneos Health
 
Alexia Tussay-Lindenberg
No Relationships to Disclose
 
Kongming Wong
Employment - Fore Biotherapeutics
 
Stacie Peacock Shepherd
Employment - Corcept Therapeutics; Fore Biotherapeutics; QED Therapeutics
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; BridgeBio Pharma; Corcept Therapeutics
Patents, Royalties, Other Intellectual Property - Patents pending for Corcept Therapeutics
 
Ping Jiang
Employment - Fore Biotherapeutics; Halozyme; Incyte
Stock and Other Ownership Interests - Fore Biotherapeutics; Incyte
 
Eric Jeffrey Sherman
Consulting or Advisory Role - Blueprint Medicines; Eisai; Exelixis; Lilly; UpToDate
Research Funding - HUTCHMED (Inst); Lilly (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron (Inst)